Mairead Kelly-Aubert
Overview
Explore the profile of Mairead Kelly-Aubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petitjean M, Letierce A, Bonnel A, Reix P, Deneuville E, Stremler N, et al.
Int Forum Allergy Rhinol
. 2025 Mar;
:e23557.
PMID: 40047648
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy...
2.
Najm M, Martignetti L, Cornet M, Kelly-Aubert M, Sermet I, Calzone L, et al.
BMC Genomics
. 2024 Sep;
25(1):892.
PMID: 39342081
Background: Cystic Fibrosis (CF) is a monogenic disease caused by mutations in the gene coding the Cystic Fibrosis Transmembrane Regulator (CFTR) protein, but its overall physio-pathology cannot be solely explained...
3.
Corrao F, Kelly-Aubert M, Sermet-Gaudelus I, Semeraro M
Expert Rev Respir Med
. 2024 May;
18(3-4):145-157.
PMID: 38755109
Introduction: 'Highly effective' modulator therapies (HEMTs) have radically changed the Cystic Fibrosis (CF) therapeutic landscape. Areas Covered: A comprehensive search strategy was undertaken to assess impact of HEMT in life...
4.
Zajac M, Lepissier A, Dreano E, Chevalier B, Hatton A, Kelly-Aubert M, et al.
Front Pharmacol
. 2023 Dec;
14:1293578.
PMID: 38149052
Cystic fibrosis (CF) is caused by defective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) proteins. CFTR controls chloride (Cl) and bicarbonate (HCO ) transport into the Airway Surface Liquid (ASL). We...
5.
Dreano E, Burgel P, Hatton A, Bouazza N, Chevalier B, Macey J, et al.
Eur Respir J
. 2023 Sep;
62(4).
PMID: 37696564
Background: Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the F508del allele on...
6.
Cornet M, Nguyen-Khoa T, Kelly-Aubert M, Jung V, Chedevergne F, Le Bourgeois M, et al.
Skin Health Dis
. 2023 Feb;
3(1):e161.
PMID: 36751320
Background: A high proportion of patients with Cystic Fibrosis (CF) also present the rare skin disease aquagenic palmoplantar keratoderma. A possible link between this condition and absence of a functional...
7.
Kelly-Aubert M, Trudel S, Fritsch J, Nguyen-Khoa T, Baudouin-Legros M, Moriceau S, et al.
Hum Mol Genet
. 2011 Apr;
20(14):2745-59.
PMID: 21518732
Cystic fibrosis (CF), a multisystem disease caused by CFTR (cystic fibrosis transmembrane conductance regulator) gene mutations, is associated with an abnormal inflammatory response and compromised redox homeostasis in the airways....